Inclusion Complexes of Non-Steroidal Anti-Inflammatory Drugs with Cyclodextrins: A Systematic Review

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2021 Mar 6

PMID 33673414

Citations 16

Authors

Gustavo Marinho Miranda

Vitoria Ohana Ramos E Santos

Jonatas Reis Bessa

Yanna C F Teles

Setondji Cocou Modeste Alexandre Yahouedehou

Marilda Souza Goncalves

Jaime Ribeiro-Filho

Affiliations

Soon will be listed here.

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used classes of medicines in the treatment of inflammation, fever, and pain. However, evidence has demonstrated that these drugs can induce significant toxicity. In the search for innovative strategies to overcome NSAID-related problems, the incorporation of drugs into cyclodextrins (CDs) has demonstrated promising results. This study aims to review the impact of cyclodextrin incorporation on the biopharmaceutical and pharmacological properties of non-steroidal anti-inflammatory drugs. A systematic search for papers published between 2010 and 2020 was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol and the following search terms: "Complexation"; AND "Cyclodextrin"; AND "non-steroidal anti-inflammatory drug". A total of 24 different NSAIDs, 12 types of CDs, and 60 distinct inclusion complexes were identified, with meloxicam and β-CD appearing in most studies. The results of the present review suggest that CDs are drug delivery systems capable of improving the pharmacological and biopharmaceutical properties of non-steroidal anti-inflammatory drugs.

Citing Articles

Approaches for Inclusion Complexes of Ezetimibe with Cyclodextrins: Strategies for Solubility Enhancement and Interaction Analysis via Molecular Docking.

Cho D, Lee J, Kim M, Cho H, Cho J, Kim K Int J Mol Sci. 2025; 26(4).

PMID: 40004150 PMC: 11855275. DOI: 10.3390/ijms26041686.

Construction of a thermosensitive gel based on hydroxypropyl-β-cyclodextrin/meloxicam inclusion complexes for improving meloxicam solubility and prolonging drug retention time in the cornea.

Yang L, Li X, Zhang Y, Tian J, Ling G, Zhang P Drug Deliv Transl Res. 2025; .

PMID: 39849286 DOI: 10.1007/s13346-025-01797-w.

Cyclodextrins: Advances in Chemistry, Toxicology, and Multifaceted Applications.

Musuc A Molecules. 2024; 29(22).

PMID: 39598708 PMC: 11596893. DOI: 10.3390/molecules29225319.

Peptide TaY Attenuates Inflammatory Responses by Interacting with Myeloid Differentiation 2 and Inhibiting NF-κB Signaling Pathway.

Wang J, Zhou Y, Zhang J, Tong Y, Abbas Z, Zhao X Molecules. 2024; 29(20).

PMID: 39459211 PMC: 11509909. DOI: 10.3390/molecules29204843.

Formulation and Development of Nanofiber-Based Ophthalmic Insert for the Treatment of Bacterial Conjunctivitis.

Farkas E, Abboud H, Nagy N, Hofmeister B, Ostorhazi E, Toth B Int J Mol Sci. 2024; 25(17).

PMID: 39273175 PMC: 11395199. DOI: 10.3390/ijms25179228.

References

Shende P, Gaud R, Bakal R, Patil D . Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies. Colloids Surf B Biointerfaces. 2015; 136:105-10. DOI: 10.1016/j.colsurfb.2015.09.002. View

Mora M, Longhi M, Granero G . Synthesis and characterization of binary and ternary complexes of diclofenac with a methyl-beta-CD and monoethanolamine and in vitro transdermal evaluation. Eur J Med Chem. 2010; 45(9):4079-88. DOI: 10.1016/j.ejmech.2010.05.068. View

Mura P, Maestrelli F, Cecchi M, Bragagni M, Almeida A . Development of a new delivery system consisting in 'drug-in cyclodextrin-in PLGA nanoparticles'. J Microencapsul. 2010; 27(6):479-86. DOI: 10.3109/02652040903515508. View

Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C . Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019; 25(12):1822-1832. PMC: 7147972. DOI: 10.1038/s41591-019-0675-0. View

Samprasit W, Akkaramongkolporn P, Ngawhirunpat T, Rojanarata T, Opanasopit P . Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins. Drug Dev Ind Pharm. 2014; 41(6):1006-16. DOI: 10.3109/03639045.2014.922573. View

Lorenzo-Veiga B, Diaz-Rodriguez P, Alvarez-Lorenzo C, Loftsson T, Sigurdsson H . In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation. Nanomaterials (Basel). 2020; 10(4). PMC: 7221994. DOI: 10.3390/nano10040709. View

Wang Z, Landy D, Sizun C, Cezard C, Solgadi A, Przybylski C . Cyclodextrin complexation studies as the first step for repurposing of chlorpromazine. Int J Pharm. 2020; 584:119391. DOI: 10.1016/j.ijpharm.2020.119391. View

Saokham P, Muankaew C, Jansook P, Loftsson T . Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes. Molecules. 2018; 23(5). PMC: 6099580. DOI: 10.3390/molecules23051161. View

Auda S . Nimesulide/methyl β-cyclodextrin inclusion complexes: physicochemical characterization, solubility, dissolution, and biological studies. Drug Dev Res. 2014; 75(2):68-75. DOI: 10.1002/ddr.21156. View

10.

Dahiya S, Kaushik A, Pathak K . Improved Pharmacokinetics of Aceclofenac Immediate Release Tablets Incorporating its Inclusion Complex with Hydroxypropyl-β-Cyclodextrin. Sci Pharm. 2016; 83(3):501-10. PMC: 4727771. DOI: 10.3797/scipharm.1509-07. View

11.

Hartlieb K, Ferris D, Holcroft J, Kandela I, Stern C, Nassar M . Encapsulation of Ibuprofen in CD-MOF and Related Bioavailability Studies. Mol Pharm. 2017; 14(5):1831-1839. DOI: 10.1021/acs.molpharmaceut.7b00168. View

12.

Gan T, Singla N, Daniels S, Lacouture P, Min L, Reyes C . Cardiovascular safety of hydroxypropyl-β-cyclodextrin-diclofenac in the management of acute postsurgical pain: a pooled analysis of 2 randomized, double-blind, placebo- and active comparator-controlled phase III clinical trials. J Clin Anesth. 2016; 31:249-58. DOI: 10.1016/j.jclinane.2016.01.020. View

13.

Noori S, Aiyer R, Yu J, White R, Mehta N, Gulati A . Nonopioid versus opioid agents for chronic neuropathic pain, rheumatoid arthritis pain, cancer pain and low back pain. Pain Manag. 2019; 9(2):205-216. DOI: 10.2217/pmt-2018-0052. View

14.

Shinde U, Joshi P, Jain D, Singh K . Preparation and Evaluation of N-Trimethyl Chitosan Nanoparticles of Flurbiprofen for Ocular Delivery. Curr Eye Res. 2019; 44(5):575-582. DOI: 10.1080/02713683.2019.1567793. View

15.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

16.

Radia O, Rogalska E, Moulay-Hassane G . Preparation of meloxicam-β-cyclodextrin-polyethylene glycol 6000 ternary system: characterization, in vitro and in vivo bioavailability. Pharm Dev Technol. 2011; 17(5):632-7. DOI: 10.3109/10837450.2011.565347. View

17.

Parra A, Clares B, Rossello A, Garduno-Ramirez M, Abrego G, Garcia M . Ex vivo permeation of carprofen from nanoparticles: A comprehensive study through human, porcine and bovine skin as anti-inflammatory agent. Int J Pharm. 2016; 501(1-2):10-7. DOI: 10.1016/j.ijpharm.2016.01.056. View

18.

Bouchal F, Skiba M, Chaffai N, Hallouard F, Fatmi S, Lahiani-Skiba M . Fast dissolving cyclodextrin complex of piroxicam in solid dispersion part I: influence of β-CD and HPβ-CD on the dissolution rate of piroxicam. Int J Pharm. 2014; 478(2):625-32. DOI: 10.1016/j.ijpharm.2014.12.019. View

19.

Gong T, Liu L, Jiang W, Zhou R . DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2019; 20(2):95-112. DOI: 10.1038/s41577-019-0215-7. View

20.

Braga S . Cyclodextrins: Emerging Medicines of the New Millennium. Biomolecules. 2019; 9(12). PMC: 6995511. DOI: 10.3390/biom9120801. View